Enveric Biosciences, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
Mailing Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
Phone (617) 444-8400
Fiscal Year End 1231
EIN 954484725
Financial Overview
FY2024
$14.67M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-1 IPO registration statement | February 10, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 6, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 4, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 2, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | December 30, 2025 | View on SEC |
Material Events
8-K Strategy Change December 11, 2025
High Impact
- Stockholders approved three key proposals: issuing shares for warrants, authorizing another potential reverse stock split (1-for-5 to 1-for-15), and increasing authorized shares from 100 million to 5 billion.
- These approvals are strategic moves aimed at maintaining Nasdaq listing, providing significant financial flexibility for future capital raises, and fulfilling existing commitments.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.